Table 2 Demographics of patients, indicating normal daily therapy and whether they were successfully blinded in this study
ID | Age (yrs) | Sex | GSD type | BMI | Normal starch treatment | Medications | Complications | Blinding success |
|---|---|---|---|---|---|---|---|---|
A | 23 | M | 1a | 21.8 | D – 120 g UCCS N –125 g polymer | Allopurinol,Ramipril, Carbamazepine Multivitamins | Seizures (stable) | Yes |
B | 24 | F | 1a | 26.0 | D – 60 g UCCS N – 55 g UCCS | Allopurinol, Ramipril. Vit B12 | PCOD Renal impairment | No – able to tell difference of taste. |
C | 25 | F | 1a | 26.7 | D – UCCS 160 g N - 120 g Polymer | Allopurinol Multivitamins | PCOD | Yes |
D | 38 | M | 1a | 22.3 | D –UCCS 200 g N – UCCS 100 g | Allopurinol simvastatin, codeine, lansoprazole | Hepatic adenoma (removed) Chronic scar pain Heartburn | No – took much less WMHMS than UCCS |
E | 16 | M | 1b | 27.1 | D – 160 g N – 175 g polymer | Allopurinol | None | No – Did not like taste of WMHMS to start but habituated |
F | 17 | M | 1b | 34.6 | D – 120 g N – 140 g polymer | Allopurinol | Obese | Yes – Thought UCCS was test starch. |
G | 19 | F | 1b | 25 | D – 90 g N – 120 g Polymer | Allopurinol GCSF | Anaemia Recurrent infections | No – able to detect different texture |
H | 18 | F | 1b | 24.9 | D – 180 g N – 120 g | Allopurinol, GCSF Co-trimoxazole Thalidomide | GSD IB enterocolitis Bronchiectasis | No – withdrew as did not like taste of WMHMS |
I | 24 | M | 1b | 19.7 | D – 160 g N – 80 g | Allopurinol GCSF | Short stature Diarrhoea | No – took much less WMHMS than UCCS. |
J | 36 | M | Ib | 22.2 | D- 30 g N- 30 g | Allopurinol Ferrous sulphate | Hepatic adenoma Chronic anaemia | No – had fewer episodes of diarrhoea with WMHMS and refused to take UCCS |